
The Fit marks the company’s first tubeless design, carrying a 300-unit insulin capacity and a seven-day wear time that does not require recharging or cartridge changes.
For continuous glucose monitor compatibility, the waterproof wearable is set to launch next year with links to MiniMed’s seven-day Simplera Sync as well as the 15-day Instinct sensor made for the company by Abbott. The patch pump will also be controlled by iOS and Android smartphone apps.
“Clearing FDA ahead of schedule is more proof we’re executing our strategy,” MiniMed CEO Que Dallara said in a statement. “It puts MiniMed Fit in U.S. customers’ hands sooner, and the pharmacy channel makes it easier to get.”
Related: MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance
The company is now planning a phased U.S. commercial rollout for spring 2027. Previously it had aimed for an autumn submission to the FDA, followed by a summer 2027 release.
Last week the agency also handed a clearance to a tubeless version of Tandem Diabetes Care’s Mobi pump, with a cartridge and infusion set that can be worn on the skin for up to a week. That 200-unit system, which requires an insulin cartridge change after three days, is scheduled for a U.S. launch in the first half of next year.
